October 21, 2021
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.
Dial-in numbers:
Please dial in 15 minutes prior to the live call.
France 0805 102 319
International 1 412 902 0128
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in
For further information, please contact:
Media:
kkirk@argenx.com
Joke Comijn (EU)
jcomijn@argenx.com
Investors:
bdelgiacco@argenx.com
mgreenblatt@argenx.com
Source: argenx SE
2021 GlobeNewswire, Inc., source